Tourmaline Bio, Inc. (TRML)
Automate Your Wheel Strategy on TRML
With Tiblio's Option Bot, you can configure your own wheel strategy including TRML - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TRML
- Rev/Share 0.0016
- Book/Share 10.0638
- PB 2.2914
- Debt/Equity 0.0006
- CurrentRatio 24.6757
- ROIC -0.395
- MktCap 592432984.0
- FreeCF/Share -3.3508
- PFCF -6.8647
- PE -6.7128
- Debt/Assets 0.0005
- DivYield 0
- ROE -0.305
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TRML | Chardan Capital Markets | -- | Buy | -- | $70 | April 23, 2025 |
| Initiation | TRML | Wedbush | -- | Outperform | -- | $42 | March 6, 2025 |
| Initiation | TRML | BMO Capital Markets | -- | Outperform | -- | $50 | Dec. 6, 2024 |
News
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Positive
Pacibekitug showed statistically significant hs-CRP reduction in CKD patients in the phase 2 TRANQUILITY study, establishing proof-of-concept for IL-6 inhibition. Positive data supports advancing pacibekitug to a phase 3 cardiovascular outcomes trial for ASCVD, pending an FDA meeting in late 2025. The 7 major Atherosclerotic Cardiovascular Disease markets are expected to reach $30.6 billion by 2035.
Read More
About Tourmaline Bio, Inc. (TRML)
- IPO Date 2021-05-07
- Website https://www.tourmalinebio.com
- Industry Biotechnology
- CEO Sandeep C. Kulkarni
- Employees 74